Page last updated: 2024-09-04

atrasentan and Bone Loss, Osteoclastic

atrasentan has been researched along with Bone Loss, Osteoclastic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Breul, J; Carducci, MA; Daliani, DD; Nabulsi, AA; Nelson, JB; Schulman, CC; Vogelzang, NJ; Zonnenberg, BA	1
Nelson, JB	1

Trials

1 trial(s) available for atrasentan and Bone Loss, Osteoclastic

Article	Year
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. The Journal of urology, 2003, Volume: 169, Issue:3 Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Double-Blind Method; Endothelin-1; Humans; Male; Peptides; Prostatic Neoplasms; Pyrrolidines	2003

Article

Year

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.

The Journal of urology, 2003, Volume: 169, Issue:3

Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Double-Blind Method; Endothelin-1; Humans; Male; Peptides; Prostatic Neoplasms; Pyrrolidines

2003

Other Studies

1 other study(ies) available for atrasentan and Bone Loss, Osteoclastic

Article	Year
Endothelin receptor antagonists in the treatment of prostate cancer. The Prostate, 2001, Oct-01, Volume: 49, Issue:2 Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Bone Resorption; Disease Progression; Endothelin Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic	2001